Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Aflibercept Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA542317

Catalog No. PIMA542317

  • $438.65 / Each of 1

    Save 25%

    Reg : $585.50

    The following deviations and disclosures may produce prices below stated discounts but will not trigger price reductions: Price shown reflects a temporary, promotional price reduction. No other purchase or commercial obligation required to receive the reduced price. Price may change at any time. Promotional price valid on web orders only. Your contract pricing may differ. Other exclusions apply.
Only null left
Add to Cart
This item is not returnable. View return policy

Description

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Biosimilars targeting aflibercept biosimilars such as Yesafili, Opuviz, and Pavblu, function by inhibiting vascular endothelial growth factor (VEGF) pathways, crucial for angiogenesis and vascular permeability. These biosimilars emulate the activity of aflibercept, a recombinant fusion protein that combines portions of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) with an immunoglobulin G (IgG) Fc fragment, effectively acting as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these growth factors, the biosimilars prevent their interaction with VEGF receptors on the surface of endothelial cells, thereby inhibiting the pathological angiogenesis and increased vascular permeability seen in conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical studies have shown that biosimilars such as SCD411, SB15, and QL1207 demonstrate comparable efficacy and safety to the reference product, aflibercept, in these indications, offering alternative treatment options that meet rigorous equivalency standards set by regulatory bodies.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Aflibercept Humanized
Recombinant Monoclonal
Unconjugated
EYLEA; Zaltrap
Human VEGFA.
100 μg
Primary
-20°C, Avoid Freeze/Thaw Cycles
Liquid
Chemical
ELISA
1.96 mg/mL
PBS with no preservative; pH 7.4
Human
Protein A/G
RUO
Human
Antibody
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.